Tisdale Risk Score Calculator – Drug-Induced QT Prolongation

Clinical calculation support · Verify results before clinical use

QTc Prolongation Risk Assessment

Select the clinical characteristics present in the hospitalized patient.

0Total score
01

Age ≥68 years

Patient age at the time of risk assessment.

+1 point
02

Female sex

Female sex as recorded for the patient.

+1 point
03

Loop diuretic administration

Receiving a loop diuretic during hospitalization.

+1 point
04

Serum potassium ≤3.5 mEq/L

Use the relevant serum potassium measurement for the assessment.

+2 points
05

Admission QTc ≥450 ms

Baseline QTc interval on admission, in milliseconds.

+2 points
06

Acute myocardial infarction

Acute MI as an admitting diagnosis or active condition.

+2 points
07

Administration of one QTc-prolonging drug

At least one medication with QTc-prolonging potential administered during hospitalization.

+3 points
08

Administration of ≥2 QTc-prolonging drugs

Two or more QTc-prolonging medications administered during hospitalization. This criterion is additional to the one-drug criterion.

+3 points
09

Sepsis

Presence of sepsis during hospitalization.

+3 points
10

Heart failure

Presence of heart failure.

+3 points
0Tisdale score
QTc prolongation risk category
Low Risk
15% observed incidence of QTc prolongation in the validation cohort.
Clinical interpretation The score is in the low-risk category. Continue clinical assessment and consider the patient's overall risk profile and planned medication exposure.

Contributing risk factors

  • No additional points selected.

Risk category estimates the likelihood of QTc interval prolongation in the study population. It does not estimate an individual probability of torsades de pointes or mortality.

About the Tisdale Risk Score

The Tisdale Risk Score is a clinical prediction tool developed to identify hospitalized patients at increased risk of QTc interval prolongation. It was derived and internally validated in patients admitted to cardiac critical care units.

The score includes demographic characteristics, clinical diagnoses, medication exposure, serum potassium, and admission QTc interval. Each risk factor contributes a weighted number of points.

Scoring criteria

Risk factorCriterionPoints
Age≥68 years1
Female sexFemale1
Loop diureticAdministration1
Serum potassium≤3.5 mEq/L2
Admission QTc≥450 ms2
Acute MIPresent2
One QTc-prolonging drugAdministered3
≥2 QTc-prolonging drugsAdministered3
SepsisPresent3
Heart failurePresent3

Risk classification

Total scoreRisk categoryObserved QTc prolongation
0–6Low15%
7–10Moderate37%
11–21High73%

Clinical application and limitations

  • The original endpoint was QTc ≥500 ms or an increase in QTc of ≥60 ms from baseline during hospitalization.
  • The original study population consisted of adult patients in cardiac critical care units with ECG/telemetry monitoring.
  • The derivation study excluded patients younger than 18 years, those discharged within 24 hours, patients without daily ECG or continuous rhythm monitoring, and those with completely paced ventricular rhythms.
  • The score does not replace ECG assessment, medication review, electrolyte evaluation, or clinical judgment.

References

Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479–487. DOI: 10.1161/CIRCOUTCOMES.113.000152
Tisdale JE, Jaynes HA, Kingery JR, et al. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2014;7(3):381–390. DOI: 10.1161/CIRCOUTCOMES.113.000651
Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation. 2010;121(8):1047–1060. DOI: 10.1161/CIRCULATIONAHA.109.192704
Tisdale JE, Chung MK, Campbell KB, et al. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. Circulation. 2020;142(15):e214–e233. DOI: 10.1161/CIR.0000000000000905
Clinical disclaimer: This calculator is intended for clinical risk stratification in hospitalized adults and is not a diagnostic tool for torsades de pointes. Risk estimates are derived from the original study population and may not generalize to all hospital settings. Assess QTc measurement, medication-specific risk, drug interactions, electrolytes, bradycardia, and other clinical factors independently. Do not use the score as the sole basis for treatment decisions.